Citius Pharmaceuticals (CTXR) Price & Analysis

Compare

1,766 Followers

CTXR Stock Chart & Stats

$1.81

-$0.64(-14.59%)

At close: Jan 08 4:00 PM EST

$1.81

-$0.64(-14.59%)

Day’s Range― - ―

52-Week Range$0.65 - $5.95

Previous CloseN/A

Volume111.57K

Average Volume (3M)1.16M

Market Cap

$21.06M

Enterprise Value$15.80M

Total Cash (Recent Filing)$6.09M

Total Debt (Recent Filing)$881.65K

Price to Earnings (P/E)―

Beta2.11

Next Earnings

Feb 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.80

Shares Outstanding18,472,190

10 Day Avg. Volume592,786

30 Day Avg. Volume1,163,736

Financial Highlights & Ratios

PEG Ratio-0.52

Price to Book (P/B)2.07

Price to Sales (P/S)0.00

P/FCF Ratio-5.15

Enterprise Value/Market Cap0.75

Enterprise Value/Revenue101.30

Enterprise Value/Gross Profit-76.72

Enterprise Value/Ebitda-0.39

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe company reported positive top-line data from the P3 study, achieving its primary endpoint of increase in time to catheter failure.

Commercialization PotentialCitius has achieved a critical milestone in future Lymphir commercialization and patient support with the assignment of a unique, permanent HCPCS J-code by the CMS.

Regulatory GuidanceThe FDA provided clear, constructive, and actionable guidance for a future New Drug Application submission for Mino-Lok, supporting its pathway to regulatory approval.

Bears Say

Capital RequirementsCitius Pharma needs to secure additional capital prior to a launch of Lymphir.

Financial ConstraintsThe company's recent quarterly report suggests the need for additional capital in the immediate future to support operations.

Regulatory Approval TimelineCompleting the steps remaining in Mino-Lok’s pathway to regulatory approval could take some time, leading to a forecasted launch in mid-2026 instead of early 2026.

Citius Pharmaceuticals News

Citius Oncology to advance launch of Lymphir with Verix AI integration

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced a deeper collaboration with Verix, a company...

6d ago

CTOR

CTXR

Citius Pharmaceuticals Announces LYMPHIR Commercialization Plans

An update from Citius Pharmaceuticals ( ($CTXR) ) is now available. On October 23, 2025, Citius Pharmaceuticals announced...

1M ago

CTXR

Citius Pharmaceuticals Secures $6M in Stock Offering

Citius Pharmaceuticals ( ($CTXR) ) just unveiled an update. On October 20, 2025, Citius Pharmaceuticals entered into a...

1M ago

CTXR

Citius Pharmaceuticals announces $6M registered direct offering priced ATM

Citius Pharmaceuticals (CTXR) announced that it has entered into definitive agreement for the purchase of an aggregate of...

1M ago

CTXR

Citius Oncology announces distribution agreement with McKesson

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced it has entered into a distribution services...

1M ago

MCK

CTOR

Citius Oncology signs exclusive commercialization agreement with EVERSANA

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced it has finalized an exclusive agreement with...

1M ago

CTOR

CTXR

Citius Oncology announces pricing of $9M registered direct offering

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced that it has entered into a securities...

3M ago

CTOR

CTXR

Citius Pharma Reports Q2 2025 Financial Results

Citius Pharma ( ($CTXR) ) has released its Q3 earnings. Here is a breakdown of the information Citius...

3M ago

CTXR

Citius Pharmaceuticals reports Q3 EPS (8c) vs.(7c) last year

As of June 30 the Company had $112 in cash and cash equivalents and 71,552,402 common shares outstanding....

4M ago

CTXR

Citius Oncology signs distribution agreement for Lymphir with Cencora

Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), executed a distribution services agreement with Cencora –...

5M ago

CTOR

CTXR

Citius Pharmaceuticals Regains Nasdaq Compliance

Citius Pharmaceuticals ( ($CTXR) ) just unveiled an update. On July 8, 2025, Citius Pharmaceuticals announced that it...

5M ago

CTXR

Citius Oncology expects commercial launch of Lymphir in second half of 2025

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced that preparations for the commercial launch of...

5M ago

CTOR

CTXR

Citius Pharmaceuticals Closes $6M Securities Offering

An update from Citius Pharmaceuticals ( ($CTXR) ) is now available. On June 9, 2025, Citius Pharmaceuticals entered...

6M ago

CTXR

Citius Pharmaceuticals price target lowered to $6 from $9 at D. Boral Capital

D. Boral Capital lowered the firm’s price target on Citius Pharmaceuticals (CTXR) to $6 from $9 and keeps...

6M ago

CTXR

CTXR FAQ

What was Citius Pharma’s price range in the past 12 months?

Citius Pharma lowest stock price was $0.65 and its highest was $5.95 in the past 12 months.

What is Citius Pharma’s market cap?

Citius Pharma’s market cap is $21.06M.

When is Citius Pharma’s upcoming earnings report date?

Citius Pharma’s upcoming earnings report date is Feb 06, 2026 which is in 71 days.

How were Citius Pharma’s earnings last quarter?

Citius Pharma released its earnings results on Aug 12, 2025. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.505 by -$0.295.

Is Citius Pharma overvalued?

According to Wall Street analysts Citius Pharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Citius Pharma pay dividends?

Citius Pharma does not currently pay dividends.

What is Citius Pharma’s EPS estimate?

Citius Pharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Citius Pharma have?

Citius Pharma has 18,472,190 shares outstanding.

What happened to Citius Pharma’s price movement after its last earnings report?

Citius Pharma reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.505. Following the earnings report the stock price went down -1.538%.

Which hedge fund is a major shareholder of Citius Pharma?

Currently, no hedge funds are holding shares in CTXR

Company Description

Citius Pharma

Citius Pharmaceuticals, Inc. (CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care, prescription products, and unique therapies using innovative delivery mechanisms. The company operates primarily in the biotechnology and healthcare sectors, leveraging its expertise to address unmet medical needs by developing and enhancing existing drug formulations.

Citius Pharmaceuticals (CTXR) Earnings & Revenues

Historic Earnings Reports

CTXR Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","11":"$11","17":"$17","23":"$23","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,5,11,17,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.29,1.1907692307692308,1.0915384615384616,0.9923076923076923,0.8930769230769231,0.7938461538461539,0.6946153846153846,0.5953846153846154,0.49615384615384617,0.39692307692307693,0.2976923076923077,0.19846153846153847,0.09923076923076923,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.29,1.1907692307692308,1.0915384615384616,0.9923076923076923,0.8930769230769231,0.7938461538461539,0.6946153846153846,0.5953846153846154,0.49615384615384617,0.39692307692307693,0.2976923076923077,0.19846153846153847,0.09923076923076923,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.29,1.1907692307692308,1.0915384615384616,0.9923076923076923,0.8930769230769231,0.7938461538461539,0.6946153846153846,0.5953846153846154,0.49615384615384617,0.39692307692307693,0.2976923076923077,0.19846153846153847,0.09923076923076923,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.92,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.44,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.16,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.58,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.64,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.97,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >